aralez pharmaceuticals  breathing new life into pharmaceuticals about about us history our company our mission leadership board of directors management we care environmental commitment portfolio portfolio cardio health bezalip sr fibricor viskazide visken yosprala zontivity toprolxl pain management cambia durela fiorinal fiorinal c mt  neovisc treximet uracyst vimovo other products balanse balanse diaflor balanse kids blexten collatamp g iberogast moviprep mutaflor   normacol pegalax proferrin purfem resultz soriatane investors stock information stock quote stock chart investment calculator stock dividendsbasis analyst coverage news releases news releases presentations  webcasts upcoming events past events presentations financial information sec filings quarterly results annual reports  proxies shareholder resources email alerts faq ir contact information corporate governance overview committee composition charterspolicies sunshine act news news aralez pharmaceuticals archive news historical presentations pozen archive news historical filings historical presentations tribute pharmaceuticals archive news historical filings historical presentations careers careers more information working at aralez recruiting agencies contact us contact us global headquarters  west credit avenue suite  mississauga ontario ln e  fax  ireland headquarters  st stephen’s green dublin  ireland  fax  us headquarters  alexander park drive princeton nj   toll free  fax  toll free fax  français about history our mission leadership management portfolio cardiovascular bezalip sr fibricor viskazide visken yosprala zontivity pain cambia durela fiorinal fiorinalc neovisc treximet uracyst vimovo mt other specialties balanse balanse diaflor balanse kids collatampg iberogast moviprep mutaflor pegalax proferrin purfem resultz investors stock information news aralez pharmaceuticals archive news historical presentations pozen pharmaceuticals archive news historical filings historical presentations tribute pharmaceuticals archive news historical filings historical presentations careers external recruiting agencies contact us learn more learn more about our portfolio investors get more information on how you can grow with us investors information cardiovascular view our portfolio page in this therapeutic category learn more about aralez the combination of pozen and tribute pharmaceuticals represents an important strategic transformation that created aralez pharmaceuticals a specialty pharmaceutical company with a compelling growth platform our portfolio the aralez portfolio of approved and investigational products is anchored in cardiovascular disease therapies with a significant pain treatment franchise and plans for continued development and growth in these and other specialty areas for investors aralez is focused on delivering meaningful products to improve patients’ lives while growing shareholder value in short medium and longterm investor information such as press releases presentations and webcasts can be found in this section    cardiovascular health pain management other products products portfolio   aralez pharmaceuticals inc hosted and managed by body portfolio  aralez pharmaceuticals about about us history our company our mission leadership board of directors management we care environmental commitment portfolio portfolio cardio health bezalip sr fibricor viskazide visken yosprala zontivity toprolxl pain management cambia durela fiorinal fiorinal c mt  neovisc treximet uracyst vimovo other products balanse balanse diaflor balanse kids blexten collatamp g iberogast moviprep mutaflor   normacol pegalax proferrin purfem resultz soriatane investors stock information stock quote stock chart investment calculator stock dividendsbasis analyst coverage news releases news releases presentations  webcasts upcoming events past events presentations financial information sec filings quarterly results annual reports  proxies shareholder resources email alerts faq ir contact information corporate governance overview committee composition charterspolicies sunshine act news news aralez pharmaceuticals archive news historical presentations pozen archive news historical filings historical presentations tribute pharmaceuticals archive news historical filings historical presentations careers careers more information working at aralez recruiting agencies contact us contact us global headquarters  west credit avenue suite  mississauga ontario ln e  fax  ireland headquarters  st stephen’s green dublin  ireland  fax  us headquarters  alexander park drive princeton nj   toll free  fax  toll free fax  français about history our mission leadership management portfolio cardiovascular bezalip sr fibricor viskazide visken yosprala zontivity pain cambia durela fiorinal fiorinalc neovisc treximet uracyst vimovo mt other specialties balanse balanse diaflor balanse kids collatampg iberogast moviprep mutaflor pegalax proferrin purfem resultz investors stock information news aralez pharmaceuticals archive news historical presentations pozen pharmaceuticals archive news historical filings historical presentations tribute pharmaceuticals archive news historical filings historical presentations careers external recruiting agencies contact us portfolio portfolio cardiovascular health pain management other products view our portfolio the aralez portfolio of approved and investigational products is anchored in cardiovascular disease therapies with a significant pain treatment franchise and plans for continued development and growth in these and other specialty areas cardiovascular product status territories marketed learn more marketed learn more marketed learn more marketed learn more marketed learn more marketed learn more marketed learn more paininflammation product status territories marketed learn more marketed learn more marketed learn more marketed learn more investigational learn more marketed learn more marketed see important warning learn more marketed learn more marketed see important warning learn more  treximet is marketed by pernix in the us  vimovo is marketed by horizon pharma in the us and astrazeneca ex – us other products dermatology product status territories marketed learn more marketed learn more gastrointestinal nonprescription products product status territories marketed learn more marketed learn more marketed learn more marketed learn more marketed learn more marketed learn more marketed learn more marketed learn more other nonprescription products product status territories marketed learn more marketed learn more marketed learn more women’s health nonprescription products product status territories marketed learn more rest of the world   aralez pharmaceuticals inc hosted and managed by body about  aralez pharmaceuticals about about us history our company our mission leadership board of directors management we care environmental commitment portfolio portfolio cardio health bezalip sr fibricor viskazide visken yosprala zontivity toprolxl pain management cambia durela fiorinal fiorinal c mt  neovisc treximet uracyst vimovo other products balanse balanse diaflor balanse kids blexten collatamp g iberogast moviprep mutaflor   normacol pegalax proferrin purfem resultz soriatane investors stock information stock quote stock chart investment calculator stock dividendsbasis analyst coverage news releases news releases presentations  webcasts upcoming events past events presentations financial information sec filings quarterly results annual reports  proxies shareholder resources email alerts faq ir contact information corporate governance overview committee composition charterspolicies sunshine act news news aralez pharmaceuticals archive news historical presentations pozen archive news historical filings historical presentations tribute pharmaceuticals archive news historical filings historical presentations careers careers more information working at aralez recruiting agencies contact us contact us global headquarters  west credit avenue suite  mississauga ontario ln e  fax  ireland headquarters  st stephen’s green dublin  ireland  fax  us headquarters  alexander park drive princeton nj   toll free  fax  toll free fax  français about history our mission leadership management portfolio cardiovascular bezalip sr fibricor viskazide visken yosprala zontivity pain cambia durela fiorinal fiorinalc neovisc treximet uracyst vimovo mt other specialties balanse balanse diaflor balanse kids collatampg iberogast moviprep mutaflor pegalax proferrin purfem resultz investors stock information news aralez pharmaceuticals archive news historical presentations pozen pharmaceuticals archive news historical filings historical presentations tribute pharmaceuticals archive news historical filings historical presentations careers external recruiting agencies contact us about more info history our company our mission leadership we care view our portfolio aralez pharmaceuticals the combination of pozen inc and tribute pharmaceuticals canada inc represents an important strategic transformation that created aralez a specialty pharmaceutical company with a compelling growth platform from which we believe we can drive significant longterm value creation aralez pharmaceuticals inc nasdaq arlz and tsx arz is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients’ lives while creating shareholder value by acquiring developing and commercializing products primarily in cardiovascular pain and other specialty areas aralez’s global headquarters is in ontario canada the us headquarters is in princeton nj and the ireland headquarters is in dublin ireland aralez has a competitive growth platform and upon formation in february  raised committed capital of  million from a deerfield partnersled syndicate that includes qlt inc broadfin capital llc and jw asset management llc enabling us to potentially accelerate our transformation and execute our growth strategy it provides a diversified growing revenue base and a geographic footprint across north america and europe with cardiovascular disease and pain management therapies being its therapeutic anchors led by a management team with a proven track record and history of success our business model is focused on strategic priorities which aim to grow a diversified business and deliver meaningful products that are capable of delivering sustainable sales growth and that offer financial and competitive advantages we strive to maintain a lean nimble and performanceoriented operating model with strong financial discipline that will allow us to build value organically and through acquisitions a key accelerator to our business strategy involves seizing high potential growth opportunities through aggressive business development and licensing with the goal of building on our anchor positions in cardiovascular disease and pain management and expanding into other specialty therapeutic areas   aralez pharmaceuticals inc hosted and managed by body management  aralez pharmaceuticals about about us history our company our mission leadership board of directors management we care environmental commitment portfolio portfolio cardio health bezalip sr fibricor viskazide visken yosprala zontivity toprolxl pain management cambia durela fiorinal fiorinal c mt  neovisc treximet uracyst vimovo other products balanse balanse diaflor balanse kids blexten collatamp g iberogast moviprep mutaflor   normacol pegalax proferrin purfem resultz soriatane investors stock information stock quote stock chart investment calculator stock dividendsbasis analyst coverage news releases news releases presentations  webcasts upcoming events past events presentations financial information sec filings quarterly results annual reports  proxies shareholder resources email alerts faq ir contact information corporate governance overview committee composition charterspolicies sunshine act news news aralez pharmaceuticals archive news historical presentations pozen archive news historical filings historical presentations tribute pharmaceuticals archive news historical filings historical presentations careers careers more information working at aralez recruiting agencies contact us contact us global headquarters  west credit avenue suite  mississauga ontario ln e  fax  ireland headquarters  st stephen’s green dublin  ireland  fax  us headquarters  alexander park drive princeton nj   toll free  fax  toll free fax  français about history our mission leadership management portfolio cardiovascular bezalip sr fibricor viskazide visken yosprala zontivity pain cambia durela fiorinal fiorinalc neovisc treximet uracyst vimovo mt other specialties balanse balanse diaflor balanse kids collatampg iberogast moviprep mutaflor pegalax proferrin purfem resultz investors stock information news aralez pharmaceuticals archive news historical presentations pozen pharmaceuticals archive news historical filings historical presentations tribute pharmaceuticals archive news historical filings historical presentations careers external recruiting agencies contact us management more info history leadership board of directors management we care view our portfolio adrian adams – chief executive officer mr adams is chief executive officer and a director of aralez pharmaceuticals inc and served in this role with the company’s predecessor pozen inc since june   prior to joining the company mr adams served as chief executive officer and president of auxilium pharmaceuticals inc from december  until its acquisition by endo international plc in january  for  billion under his leadership auxilium transformed into a men’s healthcare company and broadened its portfolio from two to twelve through the strategic corporate acquisition of actient holding llc and product inlicensing prior to joining auxilium mr adams served as chairman and chief executive officer of neurologix inc a company focused on development of multiple innovative gene therapy development programs before neurologix mr adams served as president and chief executive officer of inspire pharmaceuticals inc where he oversaw the commercialization and development of prescription pharmaceutical products and led the company through a strategic acquisition by global pharmaceutical leader merck  co inc in may  for  millionprior to inspire mr adams served as president and chief executive officer of sepracor inc from december  until its acquisition by dainippon sumitomo pharma co in february  for  billion under his leadership sepracor conducted multiple strategic corporate development activities including the inlicensing of seven products and outlicensing deals with two major pharmaceutical companies prior to its acquisition by dainippon sumitomo pharma co prior to joining sepracor mr adams was president and chief executive officer of kos pharmaceuticals inc from  until the acquisition of the company by abbott laboratories in december  for  billion during his tenure he led the transformation of kos into a fully integrated and profitable pharmaceutical company with annual revenues approaching  billion during his  years of experience mr adams also held general management and senior marketing positions at ici now part of astrazeneca smithkline beecham and novartis he has extensive international and national experience and has been instrumental in launching major global brands in addition to driving successful corporate development activities encapsulating financing product and company acquisitions inlicensing and company ma activities mr adams graduated from the royal institute of chemistry at salford university in the uk mr adams serves as chairman of the board of acelrx pharmaceuticals and recently served as a director of amylin pharmaceuticals andrew i koven – president and chief business officer mr koven is president and chief business officer of aralez pharmaceuticals inc and served in this role with the company’s predecessor pozen inc since june   mr koven has over  years of experience practicing law most of which has been in the pharmaceutical industry prior to joining the company mr koven served as executive vice president chief administrative officer and general counsel and secretary of auxilium pharmaceuticals inc from february  until its acquisition by endo international plc in january  in his role mr koven was responsible for auxilium’s legal functions government affairs and technical operations prior to auxilium mr koven served as president and chief administrative officer of neurologix inc prior to that mr koven was executive vice president and chief administrative and legal officer at inspire pharmaceuticals inc where he oversaw all matters related to legal quality and compliance corporate development and licensing and technical operations prior to the strategic acquisition of the company by merck  co from  to  mr koven served as executive vice president general counsel and corporate secretary at sepracor inc before its acquisition by dainippon sumitomo pharma co in  before joining sepracor mr koven was executive vice president general counsel and corporate secretary at kos pharmaceuticals inc where he oversaw the company’s legal compliance and quality assurance departments until the acquisition of the company by abbott laboratories in  mr koven began his career in the pharmaceutical industry as an assistant general counsel at warner lambert company from  to  followed by his role as senior vice president and general counsel at lavipharm corporation from  to  from  to  he was a corporate associate at cahill gordon  reindel in new york eric l trachtenberg – general counsel chief compliance officer  corporate secretary mr trachtenberg serves as general counsel chief compliance officer and corporate secretary of aralez pharmaceuticals inc since february   previously mr trachtenberg served as deputy general counsel of pozen inc the company’s predecessor which he joined on june   mr trachtenberg has extensive experience practicing law including over ten years in the pharmaceutical industry mr trachtenberg most recently served as deputy general counsel at auxilium pharmaceuticals inc from  through its acquisition by endo pharmaceuticals in february  prior to auxilium he was vice president general counsel and corporate secretary of enobia pharma inc and managed all legal aspects of enobia’s sale to alexion pharmaceuticals prior to that mr trachtenberg served as vice president and associate general counsel of sepracor inc and remained in that position with sunovion pharmaceuticals inc following the acquisition of sepracor by dainippon sumitomo pharma mr trachtenberg also held a senior counsel position at kos pharmaceuticals inc before its acquisition by abbott mr trachtenberg began his career as an associate at blank rome llp he holds a bachelor of science degree in management from tulane university and a juris doctorate and master of business administration degree from temple university james tursi md – chief medical officer dr james tursi is chief medical officer of aralez pharmaceuticals inc and served in this role with the company’s predecessor pozen inc since october   dr tursi has over  years of extensive experience developing pharmaceuticals across a number of therapeutic areas prior to joining the company he served as chief medical officer of innocoll ag where he was responsible for managing all clinical research and development medical affairs and safety activities prior to joining innocoll dr tursi served as chief medical officer at auxilium pharmaceuticals inc from  to  where he previously held the position of vice president of clinical research  development from  to  he was responsible for oversight of clinical and nonclinical development programs clinical operations medical affairs and global safety activities dr tursi served as the clinical medical safety lead for all regulatory agency interactions with the fda europe and canada prior to auxilium he served as director of medical affairs for glaxosmithkline biologicals from  to  and directed all medical affairs responsibilities for cervical cancer vaccines in north america dr tursi entered the pharmaceutical industry in  as a medical director for procter and gamble pharmaceuticals until  he worked on several products and therapeutic areas which included female sexual dysfunction overactive bladder and osteoporosis his responsibilities included clinical development and medical affairs dr tursi was a board certified obgyn and practiced medicine and surgery for over  years dr tursi received his doctor of medicine degree from the medical college of pennsylvania and completed his residency training at the johns hopkins hospital dr tursi serves as a member of the board of directors of agile therapeutics jennifer l armstrong – executive vice president human resources and administration ms armstrong is executive vice president of human resources and administration of aralez pharmaceuticals inc and served in this role with the company’s predecessor pozen inc since june   ms armstrong has over  years of experience in the human resources field primarily in the biotech industry prior to joining the company ms armstrong served as senior vice president of human resources at auxilium pharmaceuticals inc prior to that she served at senior vice president of human resources and corporate communications at genaera corporation during her decade long tenure at genaera ms armstrong was responsible for all facets of human resources including working directly with the compensation committee on executive and equity compensation strategies she also was responsible for investor and public relations while overseeing the it and facilities functions ms armstrong holds a master’s degree in arts administration and a bachelors degree in corporate communications both from drexel university mark a glickman – chief commercial officer mr glickman is chief commercial officer of aralez pharmaceuticals inc and served in this role with the company’s predecessor pozen inc since june   mr glickman has over  years of experience in pharmaceutical sales and operations with expertise in a variety of fields including sales turnarounds global product introductions and organizational expansions prior to joining the company mr glickman served as executive vice president of sales and marketing for auxilium pharmaceuticals prior to that he served as vice president in the medical device division at otsuka america pharmaceutical inc at otsuka he helped to reinvigorate the company’s sales and increase its business by  over two years while also spearheading quality improvement initiatives and playing a critical role in new regulatory filings prior to otsuka mr glickman served as senior vice president of sales and marketing at oscient pharmaceuticals corp during which time he completed a successful turnaround of the company’s commercial strategy driving a significant increase in sales before joining oscient mr glickman served as vice president of sales at bayer healthcare’s diabetes care division from  to  he played a major role in helping to build the commercial organization at kos pharmaceuticals and held various positions including director of marketing regional sales director and vice president of sales mr glickman started his pharmaceutical career at bristolmyers squibb where he was responsible for the marketing of cardiovascular products including the blockbuster plavix mr glickman holds a master of business administration degree from new york university scott j charles – chief financial officer mr charles is chief financial officer of aralez pharmaceuticals inc previously mr charles served as senior vice president of finance of pozen inc the company’s predecessor which he joined on july    mr charles has over  years of experience with a record of accomplishment across a spectrum of financial operations in public and private environments prior to joining the company he most recently served as the vice president of finance and treasurer at ikaria inc a critical care pharmaceutical company based in hampton new jersey with annual revenues in excess of  million mr charles played a lead role in the spinoff of ikaria’s rd operations and sale of its commercial business to a private equity firm in  for b and then to mallinckrodt in april  for b mr charles also successfully helped raise over b through numerous capital market transactions while at ikaria mr charles had the opportunity to lead all of the finance functions prior to that mr charles held several senior finance roles of increasing responsibility culminating as the vice president of finance and treasurer at reliant pharmaceuticals inc mr charles played an integral role in the company’s ma process that resulted in the successful sale of reliant to glaxosmithkline for b in  he was also instrumental in closing several business development transactions including the acquisition of lovaza a product that grew to over b in annual revenues prior to that he was a manager of assurance and business advisory services at arthur andersen llp he holds a bachelor of science degree in business administration from bucknell university and is a certified public accountant   aralez pharmaceuticals inc hosted and managed by body contact us  aralez pharmaceuticals about about us history our company our mission leadership board of directors management we care environmental commitment portfolio portfolio cardio health bezalip sr fibricor viskazide visken yosprala zontivity toprolxl pain management cambia durela fiorinal fiorinal c mt  neovisc treximet uracyst vimovo other products balanse balanse diaflor balanse kids blexten collatamp g iberogast moviprep mutaflor   normacol pegalax proferrin purfem resultz soriatane investors stock information stock quote stock chart investment calculator stock dividendsbasis analyst coverage news releases news releases presentations  webcasts upcoming events past events presentations financial information sec filings quarterly results annual reports  proxies shareholder resources email alerts faq ir contact information corporate governance overview committee composition charterspolicies sunshine act news news aralez pharmaceuticals archive news historical presentations pozen archive news historical filings historical presentations tribute pharmaceuticals archive news historical filings historical presentations careers careers more information working at aralez recruiting agencies contact us contact us global headquarters  west credit avenue suite  mississauga ontario ln e  fax  ireland headquarters  st stephen’s green dublin  ireland  fax  us headquarters  alexander park drive princeton nj   toll free  fax  toll free fax  français about history our mission leadership management portfolio cardiovascular bezalip sr fibricor viskazide visken yosprala zontivity pain cambia durela fiorinal fiorinalc neovisc treximet uracyst vimovo mt other specialties balanse balanse diaflor balanse kids collatampg iberogast moviprep mutaflor pegalax proferrin purfem resultz investors stock information news aralez pharmaceuticals archive news historical presentations pozen pharmaceuticals archive news historical filings historical presentations tribute pharmaceuticals archive news historical filings historical presentations careers external recruiting agencies contact us contact us global headquarters  west credit avenue suite  mississauga ontario ln e  fax  get map directions  ireland headquarters  st stephen’s green dublin  ireland  fax  get map directions  us headquarters  alexander park drive princeton nj   toll free  fax  toll free fax  get map directions for canadian practicing healthcare professionals and customers customer service by phone  by email email protected if you have a medical question regarding one of our products please see the following by phone  by email email protected by mail mississauga on – head office tribute pharmaceuticals  west credit avenue suite  mississauga ontario ln e if you have a medical emergency pertaining to our products please contact your physician or seek medical assistance immediately for us practicing healthcare professionals and consumers if you have a medical question or an adverse event or product complaint to report regarding one of our products please see the following by phone  by email email protected by mail aralez pharmaceuticals us inc  alexander park drive princeton nj  if you have a medical emergency pertaining to our products please contact your physician or seek medical assistance immediately business development email protected careers email protected investors nichol ochsner investor relations  corporate communications email protected   aralez pharmaceuticals inc hosted and managed by body  news releases  investors  aralez pharmaceuticals about about us historyour companyour missionleadershipboard of directorsmanagementwe careenvironmental commitmentportfolio portfolio cardio healthbezalip srfibricorviskazideviskenyospralazontivitytoprolxlpain managementcambiadurelafiorinalfiorinal cmt neovisctreximeturacystvimovoother productsbalansebalanse diaflorbalanse kidsblextencollatamp giberogastmoviprepmutaflor normacolpegalaxproferrinpurfemresultzsoriataneinvestorsstock informationstock quotestock chartinvestment calculatorstock dividendsbasisanalyst coveragenews releasesnews releasespresentations  webcastsupcoming eventspast eventspresentationsfinancial informationsec filingsquarterly resultsannual reports  proxiesshareholder resourcesemail alertsfaqir contact informationcorporate governanceoverviewcommittee compositioncharterspoliciessunshine actnewsnews aralez pharmaceuticalsnews archivehistorical presentationspozennews archivehistorical filingshistorical presentationstributenews archivehistorical filingshistorical presentationscareerscareers more informationworking at aralezrecruiting agenciescontact us contact us global headquarters  west credit avenue suite  mississauga ontario ln e  fax ireland headquarters  st stephen’s green dublin  ireland  fax us headquarters  alexander park drive princeton nj   toll free  fax  toll free fax abouthistoryour companyour missionleadershipmanagementportfoliocardiovascularbezalip srfibricorviskazideviskenyospralapaincambiadurelafiorinalfiorinalcneovisctreximeturacystvimovomtother specialtiesbalansebalanse diaflorbalanse kidsbedbugzcollatampgiberogastmoviprepmutafloroctasapegalaxproferrinpurfemresultzinvestorsstock informationstock quotestock chartinvestment calculatorstock dividendsbasisanalyst coveragenews releasespresentations  webcastsupcoming eventspast eventspresentationsfinancial informationsec filingsquarterly resultsannual reports  proxiesshareholder servicesemail alertsfaqir contact informationcorporate governanceoverviewcommittee compositioncharterspoliciessunshine actnewsaralez pharmaceuticalsnews archivehistorical filingshistorical presentationspozennews archivehistorical filingshistorical presentationstributenews archivehistorical filingshistorical presentationscareersexternal recruiting agenciescontact usnewsaralez pharmaceuticalsnews archivehistorical presentationspozentributeprint pageemail pagerss feedsemail alertsir contact informationfinancial tear sheet news releaseswebcastq  aralez pharmaceuticals inc earnings conference call live at  am etq  aralez pharmaceuticals inc earnings conference callwednesday august    am et  webcast presentation helpclick here for webcastadd to calendar help javascript must be enabled to use this feature  click here to add this event to your calendar keyword search    datetitle aralez to report second quarter  financial results on august  executive management to host conference call on august   at  am et  mississauga ontario july   prnewswire  aralez pharmaceuticals inc nasdaq arlz tsx arz today announced that it will report its second quarter  financial results on wednesday august   before the opening of the us financial markets following the announcement executive management will host a conference call and webcast at  am et on such date to discuss the companys fina aralez announces district court decision to uphold vimovo naproxenesomeprazole magnesium patentspatents covering vimovo infringed by proposed generics developed by dr reddys laboratories mylan and lupin  mississauga ontario june   prnewswire  aralez pharmaceuticals inc nasdaq arlz tsx arz aralez or the company today announced that the united states district court for the district of new jersey upheld the validity of two patents owned by a subsidiary of aralez and licensed to horizon pharma plc horizon covering vimovo® naproxenesomeprazole ma aralez announces national us commercial launch of zontivityzontivity® is the only approved proteaseactivated receptor par inhibitor a receptor for thrombin on the platelet considered to be a potent platelet activator  aralez sales representatives now targeting  cardiologists primary care physicians and vascular surgeons mississauga ontario june   prnewswire  aralez pharmaceuticals inc nasdaq arlz tsx arz aralez or the company today announced the national commercial launch of zontivity® vorapaxar in t aralez announces board member resignationmississauga ontario june   — aralez pharmaceuticals inc nasdaq arlz tsx arz the “company” today announced it received a written letter of resignation from jason m aryeh stating that he resigned effective immediately from his position on the board of directors of the company mr aryeh did not resign as a result of any current dispute or disagreement with the company mr aryeh was a valued member of the board during the period he served as a director about aralez  aralez to present at the jefferies healthcare conferencemississauga ontario may   prnewswire  aralez pharmaceuticals inc nasdaq arlz tsx arz a global specialty pharmaceutical company today announced the executive management will participate in the jefferies healthcare conference to be held june   in new york adrian adams chief executive officer will provide an overview of the company at  am local time on wednesday june   a live webcast and audio archive for the event may be accessed from the investors aralez reports first quarter  financial resultsfirst quarter  net revenues of  million cost savings plan expected to reduce  expenses by  million improved  adjusted ebitda guidance currently implementing a bold program aimed at allowing all patients to access yosprala for only  per month mississauga ontario may   prnewswire  aralez pharmaceuticals inc nasdaq arlz tsx arz aralez or the company today announced financial results for the first quarter ended march   the  aralez announces voting results from  annual and special meeting of shareholdersmississauga ontario may   prnewswire  aralez pharmaceuticals inc nasdaq arlz tsx arz aralez or the company today announced the results of the matters voted upon at the companys  annual and special meeting the meeting of the shareholders of the company the shareholders held earlier today which included the election of directors as described below  the total number of common shares of the company common shares represented by shareholders present in  aralez to report first quarter  financial results on may  executive management to host conference call on may   at  am et mississauga ontario april   prnewswire  aralez pharmaceuticals inc nasdaq arlz tsx arz today announced that it will report its first quarter  financial results on tuesday may   before the opening of the us financial markets following the announcement executive management will host a conference call and webcast at  am et on such date to discuss the companys financial res aralez announces reduction in us sales force and cost savings program reduction in the us sales force strategic realignment of resources with an emphasis on the zontivity® launch support yosprala® with direct selling efforts only company commences spend reductions across business mississauga ontario april   prnewswire  aralez pharmaceuticals inc nasdaq arlz tsx arz aralez or the company today announced that it has begun implementing a program of cost savings initiatives with the immediate aim of providing addition aralez ceo purchases  shares of company common stock on open marketmississauga ontario march   prnewswire  aralez pharmaceuticals inc nasdaq arlz tsx arz aralez or the company today announced that adrian adams the chief executive officer of the company acquired an additional  shares of the companys common stock on march   in openmarket purchases the shares were purchased at an average price of  per share for an aggregate purchase price of approximately  following this transaction mr adams owns  aralez reports fourth quarter and fullyear  financial resultsq net revenues increased to  million versus  million in the comparable period of  fullyear net revenues increased to  million versus  million in the comparable period of  provides  fullyear guidance mississauga ontario march   prnewswire  aralez pharmaceuticals inc nasdaq arlz tsx arz aralez or the company today announced financial results for the fourth quarter and fullyear ended december   the company also highli aralez to announce fourth quarter and fullyear  results on march  executive management to host conference call on march   at  am et mississauga ontario feb   prnewswire  aralez pharmaceuticals inc nasdaq arlz tsx arz today announced that it will report its  fourth quarter and fullyear financial results on monday march   before the opening of the us financial markets following the announcement executive management will host a conference call and webcast at  am et on such date to discuss the aralez to present at the rbc capital markets global healthcare conferencemississauga ontario feb   prnewswire  aralez pharmaceuticals inc nasdaq arlz tsx arz a global specialty pharmaceutical company today announced that executive management will participate in the rbc capital markets global healthcare conference to be held february   adrian adams chief executive officer will provide an overview of the company at  pm local time on wednesday february   a live webcast and audio archive for the event may be accessed  aralez to ring closing bell at nasdaq on february  mississauga ontario feb   prnewswire  aralez pharmaceuticals inc nasdaq arlz tsx arz a global specialty pharmaceutical company today announced the company will ring the nasdaq closing bell at the nasdaq marketsite in times square new york at  pm et on tuesday february   to celebrate its commitment to cardiovascular disease and the commercial launch of yosprala® chief executive officer adrian adams will perform the honorary bell ringing ceremony that w aralez pharmaceuticals unveils new office in ireland aralez announces issuance of additional us patent for yospralamississauga ontario jan   prnewswire  aralez pharmaceuticals inc nasdaq arlz tsx arz a global specialty pharmaceutical company today announced that the united states patent and trademark office uspto has issued a patent entitled compositions and methods for delivery of omeprazole plus acetylsalicylic acid that covers yosprala™ aspirin and omeprazole the only prescription fixeddose combination of an antiplatelet agent aspirin and the proton pump inhibitor omepra aralez submits marketing authorization application to the european medicines agency for pamississauga ontario jan   prnewswire  aralez pharmaceuticals inc nasdaq arlz tsx arz aralez or the company today announced that it has submitted a marketing authorization application maa to the european medicines agency ema for its investigational candidate pa for the secondary prevention of cardiovascular disease in patients at risk for aspirininduced gastric ulcers as we seek to maximize the opportunity for yosprala on a worldwide basis we plan to e aralez provides update on pbm formulary status for yospralasecures formulary status with express scripts inc for yosprala™ mississauga ontario jan   prnewswire  aralez pharmaceuticals inc nasdaq arlz tsx arz aralez or the company today announced that it has entered into a rebate agreement with express scripts inc which secures formulary status for yosprala™ the only prescription fixeddose combination of an antiplatelet agent aspirin and a proton pump inhibitor omeprazole in the united states the rebate agreement data provided by nasdaq minimum  minutes delayed   aralez pharmaceuticals about  aralez pharmaceuticals about about us history our company our mission leadership board of directors management we care environmental commitment portfolio portfolio cardio health bezalip sr fibricor viskazide visken yosprala zontivity toprolxl pain management cambia durela fiorinal fiorinal c mt  neovisc treximet uracyst vimovo other products balanse balanse diaflor balanse kids blexten collatamp g iberogast moviprep mutaflor   normacol pegalax proferrin purfem resultz soriatane investors stock information stock quote stock chart investment calculator stock dividendsbasis analyst coverage news releases news releases presentations  webcasts upcoming events past events presentations financial information sec filings quarterly results annual reports  proxies shareholder resources email alerts faq ir contact information corporate governance overview committee composition charterspolicies sunshine act news news aralez pharmaceuticals archive news historical presentations pozen archive news historical filings historical presentations tribute pharmaceuticals archive news historical filings historical presentations careers careers more information working at aralez recruiting agencies contact us contact us global headquarters  west credit avenue suite  mississauga ontario ln e  fax  ireland headquarters  st stephen’s green dublin  ireland  fax  us headquarters  alexander park drive princeton nj   toll free  fax  toll free fax  français about history our mission leadership management portfolio cardiovascular bezalip sr fibricor viskazide visken yosprala zontivity pain cambia durela fiorinal fiorinalc neovisc treximet uracyst vimovo mt other specialties balanse balanse diaflor balanse kids collatampg iberogast moviprep mutaflor pegalax proferrin purfem resultz investors stock information news aralez pharmaceuticals archive news historical presentations pozen pharmaceuticals archive news historical filings historical presentations tribute pharmaceuticals archive news historical filings historical presentations careers external recruiting agencies contact us about more info history our company our mission leadership we care view our portfolio aralez pharmaceuticals the combination of pozen inc and tribute pharmaceuticals canada inc represents an important strategic transformation that created aralez a specialty pharmaceutical company with a compelling growth platform from which we believe we can drive significant longterm value creation aralez pharmaceuticals inc nasdaq arlz and tsx arz is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients’ lives while creating shareholder value by acquiring developing and commercializing products primarily in cardiovascular pain and other specialty areas aralez’s global headquarters is in ontario canada the us headquarters is in princeton nj and the ireland headquarters is in dublin ireland aralez has a competitive growth platform and upon formation in february  raised committed capital of  million from a deerfield partnersled syndicate that includes qlt inc broadfin capital llc and jw asset management llc enabling us to potentially accelerate our transformation and execute our growth strategy it provides a diversified growing revenue base and a geographic footprint across north america and europe with cardiovascular disease and pain management therapies being its therapeutic anchors led by a management team with a proven track record and history of success our business model is focused on strategic priorities which aim to grow a diversified business and deliver meaningful products that are capable of delivering sustainable sales growth and that offer financial and competitive advantages we strive to maintain a lean nimble and performanceoriented operating model with strong financial discipline that will allow us to build value organically and through acquisitions a key accelerator to our business strategy involves seizing high potential growth opportunities through aggressive business development and licensing with the goal of building on our anchor positions in cardiovascular disease and pain management and expanding into other specialty therapeutic areas   aralez pharmaceuticals inc hosted and managed by body about  aralez pharmaceuticals about about us history our company our mission leadership board of directors management we care environmental commitment portfolio portfolio cardio health bezalip sr fibricor viskazide visken yosprala zontivity toprolxl pain management cambia durela fiorinal fiorinal c mt  neovisc treximet uracyst vimovo other products balanse balanse diaflor balanse kids blexten collatamp g iberogast moviprep mutaflor   normacol pegalax proferrin purfem resultz soriatane investors stock information stock quote stock chart investment calculator stock dividendsbasis analyst coverage news releases news releases presentations  webcasts upcoming events past events presentations financial information sec filings quarterly results annual reports  proxies shareholder resources email alerts faq ir contact information corporate governance overview committee composition charterspolicies sunshine act news news aralez pharmaceuticals archive news historical presentations pozen archive news historical filings historical presentations tribute pharmaceuticals archive news historical filings historical presentations careers careers more information working at aralez recruiting agencies contact us contact us global headquarters  west credit avenue suite  mississauga ontario ln e  fax  ireland headquarters  st stephen’s green dublin  ireland  fax  us headquarters  alexander park drive princeton nj   toll free  fax  toll free fax  français about history our mission leadership management portfolio cardiovascular bezalip sr fibricor viskazide visken yosprala zontivity pain cambia durela fiorinal fiorinalc neovisc treximet uracyst vimovo mt other specialties balanse balanse diaflor balanse kids collatampg iberogast moviprep mutaflor pegalax proferrin purfem resultz investors stock information news aralez pharmaceuticals archive news historical presentations pozen pharmaceuticals archive news historical filings historical presentations tribute pharmaceuticals archive news historical filings historical presentations careers external recruiting agencies contact us about more info history our company our mission leadership we care view our portfolio aralez pharmaceuticals the combination of pozen inc and tribute pharmaceuticals canada inc represents an important strategic transformation that created aralez a specialty pharmaceutical company with a compelling growth platform from which we believe we can drive significant longterm value creation aralez pharmaceuticals inc nasdaq arlz and tsx arz is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients’ lives while creating shareholder value by acquiring developing and commercializing products primarily in cardiovascular pain and other specialty areas aralez’s global headquarters is in ontario canada the us headquarters is in princeton nj and the ireland headquarters is in dublin ireland aralez has a competitive growth platform and upon formation in february  raised committed capital of  million from a deerfield partnersled syndicate that includes qlt inc broadfin capital llc and jw asset management llc enabling us to potentially accelerate our transformation and execute our growth strategy it provides a diversified growing revenue base and a geographic footprint across north america and europe with cardiovascular disease and pain management therapies being its therapeutic anchors led by a management team with a proven track record and history of success our business model is focused on strategic priorities which aim to grow a diversified business and deliver meaningful products that are capable of delivering sustainable sales growth and that offer financial and competitive advantages we strive to maintain a lean nimble and performanceoriented operating model with strong financial discipline that will allow us to build value organically and through acquisitions a key accelerator to our business strategy involves seizing high potential growth opportunities through aggressive business development and licensing with the goal of building on our anchor positions in cardiovascular disease and pain management and expanding into other specialty therapeutic areas   aralez pharmaceuticals inc hosted and managed by body aralez pharmaceuticals inc company information  drugscom skip to content search all allconsumerprofessionalpill idinteractionsnewsfda alertsapprovalspipelineclinical trialscare notesencyclopediadictionarynatural products browse all medications a b c d e f g h i j k l m n o p q r s t u v w x y z advanced search topics  tools facebook twitter google plus sign in sign in register menu home › pharmaceutical companies › aralez pharmaceuticals inc print share aralez pharmaceuticals inc address aralez pharmaceuticals inc  columbus circle suite  new york ny contact detailsphone  website aralezcomcareers aralezcomcareersworking drugs associated with aralez pharmaceuticals incaralez pharmaceuticals inc manufactures markets andor distributes more than  drugs in the united states medications listed here may also be marketed under different names in different countries nonus country and region specific information is not available on this page brandgeneric name average user rating fibricor generic name fenofibric acid class fibric acid derivatives na treximet generic name naproxensumatriptan class antimigraine agents      vimovo generic name esomeprazolenaproxen class nonsteroidal antiinflammatory agents      yosprala generic name aspirinomeprazole class platelet aggregation inhibitors na latest drug information updates vosevi vosevi sofosbuvir  velpatasvir  voxilaprevir is a singletablet regimen for the treatment of adults withnerlynx nerlynx neratinib is a tyrosine kinase inhibitor for the extended adjuvant treatment of patients with earlytremfya tremfya guselkumab is an interleukin blocker indicated for the treatment of adult patients withbevyxxa bevyxxa betrixaban is an oral oncedaily factor xa inhibitor anticoagulant for the extendeddurationrituxan hycela rituxan hycela rituximab and hyaluronidase human is a subcutaneous monoclonal antibody and hyaluronidasebaxdela baxdela delafloxacin is a fluoroquinolone antibacterial indicated for the treatment of acute bacterial skin more drug information updates drugscom mobile apps the easiest way to lookup drug information identify pills check interactions and set up your own personal medication records available for android and ios devices explore apps support help center frequent questions sitemap contact us about about drugscom advertising policy content submissions drugscom blog terms  privacy editorial policy privacy policy terms of use attribution  citations facebook twitter google plus youtube rss feed subscribe to receive email notifications whenever new articles are published drugscom provides accurate and independent information on more than  prescription drugs overthecounter medicines and natural products this material is provided for educational purposes only and is not intended for medical advice diagnosis or treatment data sources include micromedex® updated july th  cerner multum™ updated july th  wolters kluwer™ updated july th  and others to view content sources and attributions please refer to our editorial policy third party advertising we comply with the honcode standard for trustworthy health information  verify here copyright   drugscom all rights reserved share on facebook share on twitter share on googleplus email to a friend hide aralez pharmaceuticals inc company profile  bloomberg feedback aralez pharmaceuticals inc public company company profile sector health care industry biotech  pharma subindustry specialty pharma aralez pharmaceuticals inc operates as a pharmaceutical company the company focuses on acquiring developing and commercializing products primarily in cardiovascular pain and other specialty areas aralez pharmaceuticals serves customers worldwide corporate information address  steeles ave e milton on lt y canada phone  fax  web url wwwaralezcom board members chairman company chief executive officer company adrian adams aralez pharmaceuticals inc board members company seth rudnick highcape partners management lp neal fowler liquidia technologies inc show more from the web key executives adrian adams chief executive officer andrew i koven preschief business officer scott j charles chief financial officer eric l trachtenberg chief compliance ofcrsecygen cnsl james p tursi chief medical ofcr mark a glickman chief commercial ofcr jennifer l armstrong exec vphuman resources  adminstration nichol ochsner exec dirinvestor relations  corporate comm sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data arlz key statistics  aralez pharmaceuticals inc financial ratios  marketwatch bulletin investor alert new york markets open in market snapshot analyst ratings expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close aralez pharmaceuticals inc nasdaq arlz go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus aralez pharmaceuticals inc after hours  quotes are delayed by  min jul    pm arlz quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   company description aralez pharmaceuticals inc operates as a pharmaceutical company it focuses on the development acquisition and commercialization of cardiovascular pain and other product therapies the company is founded on december   and is headquartered in ontario canada       valuation pe current  pe ratio with extraordinary items  price to sales ratio  price to book ratio  enterprise value to ebitda  enterprise value to sales  total debt to enterprise value  efficiency revenueemployee  income per employee  receivables turnover  total asset turnover  liquidity current ratio  quick ratio  cash ratio  profitability gross margin  operating margin  pretax margin  net margin  return on assets  return on equity  return on total capital  return on invested capital  capital structure total debt to total equity  total debt to total capital  total debt to total assets  longterm debt to equity  longterm debt to total capital  officers and executives name age officer since title mr adrian adams   chief executive officer  director mr andrew i koven   president  chief business officer mr scott j charles   chief financial officer dr james patrick tursi   chief medical officer ms jennifer lou armstrong   executive vphuman resources  administration insider actions – purchase – sale  – number of transactions  date name shares transaction value  eric l trachtenberg gc cco  secretary    disposition at  per share   arthur s kirsch director    acquisition at  per share   arthur s kirsch director    acquisition at  per share   andrew i koven president  chief business off    disposition at  per share   adrian adams chief executive officer director    award at  per share   robert paul harris director    award at  per share   francis martin thrasher director    award at  per share   scott j charles chief financial officer    award at  per share   james patrick tursi chief medical officer    award at  per share   mark a glickman chief commercial officer    award at  per share   arthur s kirsch director    award at  per share   eric l trachtenberg gc cco  secretary    award at  per share   jennifer lou armstrong evp hr and administration    award at  per share   seth a rudnick director    award at  per share   andrew i koven president  chief business off    award at  per share   kenneth b lee director    award at  per share   neal f fowler director    award at  per share   jason m aryeh director    award at  per share   scott j charles chief financial officer    disposition at  per share   andrew i koven president  chief business off    disposition at  per share   adrian adams chief executive officer director    acquisition at  per share   james patrick tursi chief medical officer    acquisition at  per share   arthur s kirsch director    acquisition at  per share   seth a rudnick director    acquisition at  per share   andrew i koven president  chief business off    acquisition at  per share   kenneth b lee director    acquisition at  per share   robert paul harris director    disposition at  per share   robert paul harris director    derivativenonderivative trans at  per share   robert paul harris director    disposition at  per share   robert paul harris director    derivativenonderivative trans at  per share   seth a rudnick director    gift at  per share   seth a rudnick director    gift at  per share  newslatestcompanyusarlz marketwatch news on arlz astrazeneca sells us rights for toprolxl  am oct    marketwatchcom  stocks to watch  pm june    the trading deck  cheapest stocks in the nasdaq’s hottest sector  pm feb    philip van doorn cypress spansion shares rally on merger plan  pm dec    wallace witkowski sigma designs pozen shares jump after hours  pm sept    wallace witkowski sanofi pozen sign deal on aspirin products  pm sept    marketwatchcom pozen shares jump  on sanofi license deal  pm sept    wallace witkowski hedge funds are buying these stocks right now  pm july    insider monkey bed bath  beyond stocks slide after hours  pm june    carla mozee pozen fda disagrees with aspirinpill finding  pm june    marketwatchcom pozen inc up  in premarket  am march    steve gelsi stocks to watch monday netflix amazon pozen  am nov    david b wilkerson friday’s biggest gaining and declining stocks  pm nov    myra p saefong us stocks end lower dow loses  on week  pm nov    myra p saefong pozen sees year loss affirms royalty revenue  am oct    marketwatchcom monday’s biggest gaining and declining stocks  pm oct    kate gibson alexza leads drug stocks south  pm oct    val brickates kennedy pozen gains on eu nod for pain reliever vimovo  am oct    val brickates kennedy astrazeneca gets positive eu agreement on vimovo  am oct    simon kennedy pfizer leads drug stocks north akorn slides  pm aug    val brickates kennedy loading more headlines newsnonmarketwatchcompanyusarlz other news on arlz aralez a quick overview of the investment thesis  pm july    seeking alpha aralez to report second quarter  financial results on august    am july    cnw group an upcoming conversation with a cardiologist on the market potential for aralez pharmas zontivity and yosprala  pm july    seeking alpha biotech forum daily digest  celgene continues to make deals spotlight on xenon  pm july    seeking alpha update on aralez pharmaceuticals  am july    seeking alpha for aralez time to turn it around  pm june    seeking alpha aralez pharmaceuticals inc arlz scores a win in patent dispute  am june    smarteranalyst aralez announces district court decision to uphold vimovo naproxenesomeprazole magnesium patents  am june    cnw group aralez pharmaceuticals arlz presents at jefferies  global healthcare conference  slideshow  pm june    seeking alpha aralez announces national us commercial launch of zontivity  am june    seeking alpha aralez announces national us commercial launch of zontivity  am june    cnw group aralez announces board member resignation  am june    cnw group aralez to present at the jefferies healthcare conference  am may    cnw group q aralez pharmaceuticals inc  pm may    edgar online  edg  q k aralez pharmaceuticals arlz ceo adrian adams on q  results  earnings call transcript  pm may    seeking alpha aralez pharmaceuticals arlz ceo adrian adams on q  results  earnings call transcript  pm may    seeking alpha aralez pharmaceuticals inc  q  results  earnings call slides  am may    seeking alpha premarket gainers as of  am  am may    seeking alpha aralez reports first quarter  financial results  am may    cnw group aralez announces voting results from  annual and special meeting of shareholders  pm may    cnw group loading more headlines at a glance aralez pharmaceuticals inc  west credit avenue suite  mississauga ontario ln e phone   industry pharmaceuticals sector health carelife sciences fiscal yearend  view sec filings revenue m net income m  sales growth  employees  annual report for arlz newspressreleasecompanyusarlz press releases on arlz aralez to report second quarter  financial results on august    am july    pr newswire  prf todays research reports on theratechnologies inc vbi vaccines inc aralez pharmaceuticals inc and immunovaccine inc  am july    accesswire corporate news blog  aralez announced district court decision to uphold vimovo patents  am june    accesswire aralez announces national us commercial launch of zontivity  am june    pr newswire  prf biotech stocks on investors radar  achillion pharma acorda therapeutics aralez pharma and regulus therapeutics  am may    pr newswire  prf aralez to present at the jefferies healthcare conference  am may    pr newswire  prf industry veterans joins xorlabs toronto  am may    marketwired todays research reports on stocks to watch dryships and aralez pharmaceuticals  am may    accesswire investor network aralez pharmaceuticals inc to host earnings call  am may    accesswire aralez reports first quarter  financial results  am may    pr newswire  prf aralez announces voting results from  annual and special meeting of shareholders  pm may    pr newswire  prf aralez to report first quarter  financial results on may    am april    pr newswire  prf todays research reports on stocks to watch aralez pharmaceuticals and innocoll holdings  am april    accesswire aralez announces reduction in us sales force and cost savings program  am april    pr newswire  prf horizon pharma plc announces the us patent and trademark office issuance of an additional notice of allowance with claims covering vimovor naproxenesomeprazole delayed release tablets  am march    globenewswire biotech stocks on investors radar  editas intracellular aralez pharma and catabasis pharma  am march    pr newswire  prf aralez ceo purchases  shares of company common stock on open market  am march    pr newswire  prf aralez to announce fourth quarter and fullyear  results on march    am feb    pr newswire  prf aralez to present at the rbc capital markets global healthcare conference  pm feb    pr newswire  prf aralez pharmaceuticals inc nasdaq arlz to ring the nasdaq stock market closing bell  am feb    globenewswire loading more headlines trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest aftse  gains ground as itv bounces up gdp data on deck abrits don’t want america’s chlorinated chickens in their supermarkets a stocks for betting on the rush away from cash ahere’s why oil just scored its biggest oneday rally of  anintendo holds to switch sales view despite demand apetrofac wins  million in contracts in iraq agkn earnings rise offers upbeat  outlook afrench consumer confidence drops sharply atullow oil swings to loss on impairment aitv rises  after dividend hike agermanys dax opens  point lower at  afrances cac  opens  higher at  auks ftse  opens  higher at  astoxx europe  opens  higher at  aantofagasta gold copper production rises athree ways draghi could burn the euro bulls afresnillo gold silver production rises aitv profit falls  but dividend is raised ahow china not trump trade is now lifting copper aaustralian inflation more muted than seen loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  aralez pharmaceuticals inc arlz stock message board  investorshub support   newswire  home  log in boards stocks commodities forex cryptocurrency the lounge hot breakout boards ihub my stocks activity ticker buzz cloud most read most posted most followed members recent news active boards site stats new boards cannabis stocks tools data tools  charts trader alerts trades portfolio top lists price  news alerts commodities markets in d newswire more tools  newsletters my image gallery advanced search videos all news stock screener news filter live charts live news live desktop forex prices commodities etf center educational channel personal finance qa streamer level  follow feed home  boards  us listed  medical  drugs  aralez pharmaceuticals inc arlz add arlz price alert      hide sticky   hide intro moderator drugdoctor search this board                 created   pm  followers   board type free  posts today  description aralez pharmaceuticals inc operates as a specialty pharmaceutical company in canada ireland and the united states it engages in acquiring developing and commercializing products primarily in cardiovascular disease pain and other specialty areas it offers fibricor a fenofibric acid for the treatment of severe hypertriglyceridemia cambia a nonsteroidal antiinflammatory drug nsaid for the acute treatment of migraine attacks fiorinal and fiorinal c for the relief of tension type headaches soriatane a retinoid an aromatic analog of vitamin a for the treatment of severe psoriasis and other disorders of keratinization and bezalip sr a panperoxisome proliferatoractivated receptor activator to treat hyperlipidemia as well as to increase insulin sensitivity and decrease blood glucose levels for the patients with metabolic syndrome it also markets neovisc a sodium hylauronic solution uracyst a sodium chondroitin sulfate durela a tramadol hydrochloride proferrin a heme iron polypeptide resultz a isopropyl myristate collatamp g a collagengentamycin and a portfolio of eight products targeted for the areas of gastroenterology and womens health in addition it develops yosprala  and  for secondary prevention of cardiovascular and cerebrovascular disease in patients at risk for gastric ulcers which have completed phase iii clinical development in the united states and bilastine an antihistamine drug for the treatment of allergic rhinoconjunctivitis and urticaria further its outlicensed products include vimovo for the relief of the signs and symptoms of osteoarthritis rheumatoid arthritis and ankylosing spondylitis as well as to decrease the risk of developing gastric ulcers in patients at risk of developing nsaidassociated gastric ulcers and treximet a migraine medicine the company is headquartered in milton canada corporate governance aralez pharmaceuticals inc’s iss governance qualityscore as of march   is  the pillar scores are audit  board  shareholder rights  compensation  corporate governance scores courtesy of institutional shareholder services iss scores indicate decile rank relative to index or region a decile score of  indicates lower governance risk while a  indicates higher governance risk aralez pharmaceuticals inc  steeles avenue east milton on lt y canada  httpwwwaralezcom sector  industry  full time employees key executives name title pay exercised age mr adrian adams chief exec officer and director m na  mr andrew i koven pres and chief bus officer k na  mr scott j charles chief financial officer k na  mr mark a glickman chief commercial officer k na  mr john e barnhardt cpa principal accounting officer and vp of fin  admin na na  amounts are as of december   and compensation values are for the last fiscal year ending on that date pay is salary bonuses etc exercised is the value of options exercised during the fiscal year currency in usd   aralez reports first quarter  financial results   news provided by aralez pharmaceuticals inc   may   et share this article             first quarter  net revenues of  million cost savings plan expected to reduce  expenses by  million improved  adjusted ebitda guidance   currently implementing a bold program aimed at allowing all patients to access yosprala for only  per month mississauga ontario may   prnewswire  aralez pharmaceuticals inc nasdaq arlz tsx arz aralez or the company today announced financial results for the first quarter ended march   the company also highlighted certain recent corporate and commercial achievements all figures are in us dollars we are pleased to report a solid first quarter of  together with important updates to our business addressing a number of the challenges we face said adrian adams chief executive officer of aralez we are making a bold and significant change to our pricing strategy for yosprala® aimed at allowing all patients to access the product for only  per month in addition we continue to implement our cost savings plan to further improve our cost structure and balance sheet to maximize and preserve our financial flexibility our updated financial guidance for  reflects our commitment to reaching breakeven on an adjusted ebitda basis this year we also continue to opportunistically look at business development opportunities with a strong focus on value creating and transformative ma with the goal of enhancing shareholder value company highlights the company is currently implementing a bold patient friendly program aimed at allowing all patients to access yosprala for only  per month regardless of coverage or copay level set by the insurer this program will be available for all patients through retail pharmacies or through select national mail order partners the company has begun implementing cost savings initiatives that are expected to reduce our  operating expenses by approximately  million of which approximately  million was included in our original  adjusted ebitda guidance in addition the company has also identified other initiatives to drive an increase in profitability such as an increased focus on the canadian core growth brands and the board of directors recent decision to reduce the cash portion of their fees for  by half on may   aralez subsidiary pozen inc pozen entered into a license agreement with a multinational pharmaceutical company pursuant to which pozen granted a nonexclusive license to such company under a japanese patent owned by pozen the nonexclusive license is limited to japan in consideration for this nonexclusive license pozen will receive an upfront payment of  million plus contingent milestone payments and royalties under certain circumstances on april   the company commenced its phased launch of zontivity® utilizing  sales representatives deployed to high volume physicians who treat postmyocardial infarction mi and peripheral artery disease pad patients the phase  fullscale launch is expected to begin in early june  with  sales representatives targeting approximately  physicians made up of cardiologists primary care and vascular surgeons on april   aralez pharmaceuticals us inc apus and the united states government the government entered into a modification of contract for toprolxl® pursuant to which the government exercised its first renewal option under the va national contract between apus and the government the va contract extending the term of the va contract by one year to april   with reduced pricing for the duration thereof  deerfield partners remains fully supportive of aralez and its management team as the company navigates its way through recent challenges said james flynn managing partner at deerfield we are encouraged by the new pricing strategy for yosprala and the prospects for zontivity cost savings initiatives  the company previously announced in april  that it had begun implementing cost savings initiatives as part of the companys ongoing objective to maximize value from its assets and preserve financial flexibility the total expected operating expense reduction in  of approximately  million includes the previously announced  reduction in its us sales force which is expected to yield  savings of approximately  million  million on an annual basis a decrease of approximately  million in  commercial spend which primarily relates to nondirect marketing spend on yosprala and decreased  departmental expenses across the business of approximately  million while aralez has made significant reductions to its expenses the company plans to invest an additional  million to support a successful phased launch of zontivity that commenced on april   which the company views as an increasingly attractive opportunity the company also continues to assess various business development opportunities with the goal of providing improved cash flow and an enhanced platform for creating value first quarter  financial results  aralezs financial results for the three months ended march   include the operations of tribute pharmaceuticals canada inc tribute from february   the closing date of the pozen and tribute merger transaction the merger through march   but do not include the results of zontivity or toprolxl and its currently marketed authorized generic the toprolxl franchise as these acquisitions were completed on september   and october   respectively aralezs financial results for the three months ended march   include the results of tribute zontivity and the toprolxl franchise total revenues for the three months ended march   were  million compared to  million for the three months ended march   net product revenues of  million for the three months ended march   primarily related to the product portfolio acquired with the acquisition of tribute as well as net product revenues from yosprala and fibricor® other revenues of  million for the three months ended march   were comprised of net revenues of  million from the acquisitions of the toprolxl franchise and zontivity which are recorded net of related cost of product revenues and fees paid during the respective transition service periods and vimovo® royalties of  million pursuant to the companys agreement with horizon in the us subject to certain conditions described in our public filings aralez is guaranteed a quarterly minimum royalty amount calculated based on a minimum annual royalty of  million which was reflected in the companys first quarter results net product revenues of  million for the three months ended march   related to the tribute product portfolio acquired in the merger which was completed on february   other revenues of  million for the three months ended march   were comprised solely of vimovo royalties cost of product revenues were  million for the three months ended march   compared to  million for the three months ended march   the increase related primarily to costs of product revenues for the full quarter in  from the companys product portfolio that was acquired as part of the merger in february  sga expenses were  million for the three months ended march   compared to  million for the three months ended march   the decrease in sga expenses was primarily driven by costs related to the merger in the prior year of approximately  million partially offset by increased costs related to the build out of our us sales force in  and increased promotional expenses in the us during the first quarter of  rd expenses for the three months ended march   were  million compared to  million for the three months ended march   the decrease related primarily to higher costs incurred in the first quarter of  for yosprala in advance of its us approval in september  amortization of intangible assets of  million for the three months ended march   related to the acquisitions of tribute zontivity and the toprolxl franchise amortization of intangible assets for the three months ended march   of  million related solely to the acquisition of tribute the change in fair value of contingent consideration of  million for the three months ended march   related to accretion for the toprolxl franchise and zontivity acquisitions there was no expense related to fair value changes in contingent consideration for the three months ended march   interest expense of  million for the three months ended march   was primarily attributable to the borrowing of  million under the companys credit facility in the fourth quarter of  in connection with the acquisitions of zontivity and the toprolxl franchise and  million convertible notes interest expense of  million for the three months ended march   related to the  million convertible notes other income net for the three months ended march   was  million compared to  million for the three months ended march   a decrease of  million the decrease principally related to a  million decrease in the fair value of the warrants liability acquired from tribute during the prior year offset by a  million gain from the sale of a building in london ontario during the three months ended march   the net loss for the three months ended march   was  million or  loss per share on a fully diluted basis compared to a net loss for the three months ended march   of  million or  loss per share on a fully diluted basis adjusted ebitda was  million for the three months ended march   compared to adjusted ebitda of  million for the three months ended march   balance sheet  as of march   approximately  million of the companys common shares were issued and outstanding and the company had cash and cash equivalents of approximately  million updated  guidance  aralezs estimates are based on projected results of the company for the year ending december   and reflect managements current beliefs and expectations about among other things prescription trends competition pricing levels inventory levels and anticipated future events the companys guidance on adjusted ebitda includes among other things costs to support the commercialization efforts with respect to yosprala zontivity and the canadian product portfolio as well as costs to support the global corporate structure it excludes sharebased compensation expense and certain discrete costs including merger and product acquisitionrelated expenses see use of nongaap financial measures below    for the year ending december   assuming among other factors more particularly set out in cautionary note regarding forwardlooking statements below the company currently expects  net revenues to be in a range of  million to  million and updated  adjusted ebitda to be in a range of  million to  million see the table below for a comparison of the companys original  guidance compared to the updated  guidance   measure  original guidance  updated guidance net revenues  million to  million  million to  million adjusted ebitda  million to  million  million to  million first quarter results webcast  aralez will host a webcast this morning may   at  am et to present results for the first quarter  the webcast can be accessed live and will be available for replay at wwwaralezcom conference call details  date tuesday may    time  am et  dialin us    dialin international  about aralez pharmaceuticals inc  aralez pharmaceuticals inc nasdaq arlz tsx arz is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients lives while creating shareholder value by acquiring developing and commercializing products primarily in cardiovascular pain and other specialty areas aralezs global headquarters is in ontario canada the us headquarters is in princeton new jersey and the irish headquarters is in dublin ireland more information about aralez can be found at wwwaralezcom     arlz current price volume bid ask days range arlz detailed quote dmmmmyyyy arlz news aralez to report second quarter  financial results on august     am arlz news aralez to report second quarter  financial results on august     am arlz news current report filing k   am arlz news aralez announces district court decision to uphold vimovo naproxenesomeprazole magnesium patents   am arlz news aralez announces district court decision to uphold vimovo naproxenesomeprazole magnesium patents   am post new msg follow board my stocks  hide intro view posters arlz poststream bans  hide quote filter disabled postsubject older    arlz buy  stocktrademan   am    yep bottom was confirmed now lets see if drugdoctor   am    trying to print a bottom drugdoctor   pm      arlz video chart    claytrader   pm    yeah same here looks like arry and exel island man   pm    ceo loaded a bunch of shares in the drugdoctor   am    arlz aralez pharmaceuticals last signalbuy last patternbullish piercing line l mrpopeye   pm    aralez pharmaceuticals nasdaqarlz arthur s kirsch director buy    mrpopeye   pm    im currently out  stock is downtrending will drugdoctor   pm    been getting hit hard ar adxs trading a island man   pm    probably a smart move as it fell right drugdoctor   pm    closed the position  nice profit move it island man   pm    you may have struck the bottom with that drugdoctor   pm    k shares   island man   pm    did you get em im not loading drugdoctor   pm    have a stink bid at  island man   pm    arlz still trending higher has such a long drugdoctor   am    aralez reports first quarter  financial results drugdoctor   am    thanks pete  daily certainly looks stronger than drugdoctor   am    arlz daily and weekly chart httpstockchar pistol pete   am    yea the company has done what it needs drugdoctor   pm    wow nice clay this stock can really benefit drugdoctor   pm      arlz video chart    claytrader   pm    nice pop today the ship is turning island man   pm    it appears the market likes the earnings news drugdoctor   am    yea earnings tomorrow they need to show great hope drugdoctor   pm    well lets hope the whole bio industry turns island man   pm    got a nice bottom reversal going today lets drugdoctor   am    the k says there is new investor presentation drugdoctor   am    i agree and once they become net profitable drugdoctor   pm    yeah doc been adding some shares sub  island man   pm    im adding a little here as i think drugdoctor   pm    it appears they got the va contract for drugdoctor   pm    the cash burn had to be slowed for drugdoctor   am    yes id wait a few days though the drugdoctor   pm    might be a good time to nibble in island man   pm    news out this afternoon with regards to healthcare island man   pm    yea i didnt hear about that so thanks drugdoctor   am    hey doc sold yesterday for k profitbought island man   pm    yes obviously still funds liquidating positions as they drugdoctor   pm    just looking into thisany reason for the drop iron maiden   pm    we may have a gap and go today jess   am    arlz  pressrelease out  news investorshubadvfncomuimage drugdoctor   am    yeah i gathered you meant dollars and not island man   pm    yea i feel really good about my investment drugdoctor   pm    good you grabbed some this is a low island man   pm    yea i grabbed a few thousand thursday and drugdoctor   pm    well well always good to see insiders buying island man   pm    i will be buying more monday if the drugdoctor   am    now thats a power play viperdeal   am postsubject older post new msg follow board my stocks  hide intro view posters arlz poststream bans  hide quote filter disabled   investorshubcom inc about investor relations about us terms of service privacy policy advertise with us data accreditations disclaimer help faq handbook qa forum contact us tutorials educational educational channel stock market  educational videos investor help forum personal finance qa more corporate solutions ihub on facebook ihub on twitter ihub iphoneipad app ihub android app ihub blackberry app ihub newswire you are guest on web   aralez pharmaceuticals inc k may    am  seeking alphasign in  join nowgo»aralez pharmaceuticals inc arlzform k  current reportmay    amabout aralez pharmaceuticals inc arlzview as pdf aralez pharmaceuticals inc form k received       united states securities and exchange commission washington dc  form k current report pursuant to section  or dof the securities exchange act of  date of report date of earliest event reported  may   aralez pharmaceuticals inc exact name of registrant as specified in its charter       british columbia canada   state or other jurisdiction of commission file number irs employer identification no incorporation              west credit avenue suite  mississauga ontario canada ln e address of principal executive offices zip code   registrant’s telephone number including area code   not applicable former name or former address if changed since last report check the appropriate box below if the form k filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions     ☐ written communications pursuant to rule under the securities act  cfr      ☐ soliciting material pursuant to rulea under the exchange act  cfr a     ☐ precommencement communications pursuant to ruledbunder the exchange act  cfr db     ☐ precommencement communications pursuant to ruleecunder the exchange act  cfr ec   indicate by check mark whether the registrant is an emerging growth company as defined in rule  of the securities act of  § of this chapter or rule b of the securities exchange act of  §b of this chapter   emerging growth company                                 ☐   if an emerging growth company indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section a of the exchange act     ☐           item  results of operations and financial condition on may   aralez pharmaceuticals inc a company formed under the laws of the province of british columbia canada the “company” issued a press release announcing its results of operations for the quarter ended march   the full text of such press release is furnished as exhibit  to this report and is incorporated herein by reference item  regulation fd disclosures as previously announced the company will conduct a conference call today tuesday  may   at  am et to discuss its  first quarter financial results and recent highlights the presentation slides to be used during the call will be available on the “investors” section of the company’s website httpwwwaralezcom under the “presentations  webcasts” tab beginning at  am et on tuesday  may   a question and answer session will follow the presentation the conference call and the presentation slides will be simultaneously webcast on the “investors” section of the company’s website under the “presentations  webcasts” tab beginning at  am et on tuesday  may   and will remain available for future review for two weeks after the event the information contained in or that can be accessed through the company’s website is not a part of this filing item  financial statements and exhibits d  list of exhibits         exhibit no   description          press release dated may   issued by aralez pharmaceuticals inc       signature pursuant to the requirements of the securities exchange act of  the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized       date may   aralez pharmaceuticals inc         by s andrew i koven     andrew i koven     president and chief business officer         exhibit index         exhibit no   description          press release dated may   issued by aralez pharmaceuticals inc       exhibit  click to enlarge aralez reports first quarter  financial results first quarter  net revenues of  million cost savings plan expected to reduce  expenses by  million improved  adjusted ebitda guidance currently implementing a bold program aimed at allowing all patients to access yosprala for only  per month mississauga ontario may   —  aralez pharmaceuticals inc nasdaq arlz tsx arz   aralez or the company    today announced financial results for the first quarter ended march   the company also highlighted certain recent corporate and commercial achievements all figures are in us dollars “we are pleased to report a solid first quarter of  together with important updates to our business addressing a number of the challenges we face” said adrian adams chief executive officer of aralez “we are making a bold and significant change to our pricing strategy for yosprala   aimed at allowing all patients to access the product for only  per month in addition we continue to implement our cost savings plan to further improve our cost structure and balance sheet to maximize and preserve our financial flexibility our updated financial guidance for  reflects our commitment to reaching breakeven on an adjusted ebitda basis this year we also continue to opportunistically look at business development opportunities with a strong focus on value creating and transformative ma with the goal of enhancing shareholder value” company highlights · the company is currently implementing a bold patient friendly program aimed at allowing all patients to access yosprala for only  per month regardless of coverage or copay level set by the insurer this program will be available for all patients through retail pharmacies or through select national mail order partners · the company has begun implementing cost savings initiatives that are expected to reduce our  operating expenses by approximately  million of which approximately  million was included in our original  adjusted ebitda guidance in addition the company has also identified other initiatives to drive an increase in profitability such as an increased focus on the canadian core growth brands and the board of directors recent decision to reduce the cash portion of their fees for  by half · on may   aralez subsidiary pozen inc pozen entered into a license agreement with a multinational pharmaceutical company pursuant to which pozen granted a nonexclusive license to such company under a japanese patent owned by pozen the nonexclusive license is limited to japan in consideration for this nonexclusive license pozen will receive an upfront payment of  million plus contingent milestone payments and royalties under certain circumstances · on april   the company commenced its phased launch of zontivity  utilizing  sales representatives deployed to high volume physicians who treat postmyocardial infarction mi and peripheral artery disease pad patients the phase  fullscale launch is expected to begin in early june  with  sales representatives targeting approximately  physicians made up of cardiologists primary care and vascular surgeons · on april   aralez pharmaceuticals us inc apus and the united states government the government entered into a modification of contract for toprolxl   pursuant to which the government exercised its first renewal option under the va national contract between apus and the government the va contract extending the term of the va contract by one year to april   with reduced pricing for the duration thereof deerfield partners remains fully supportive of aralez and its management team as the company navigates its way through recent challenges said james flynn managing partner at deerfield we are encouraged by the new pricing strategy for yosprala and the prospects for zontivity   cost savings initiatives the company previously announced in april  that it had begun implementing cost savings initiatives as part of the company’s ongoing objective to maximize value from its assets and preserve financial flexibility  the total expected operating expense reduction in  of approximately  million includes the previously announced  reduction in its us sales force which is expected to yield  savings of approximately  million  million on an annual basis a decrease of approximately  million in  commercial spend which primarily relates to nondirect marketing spend on yosprala and decreased  departmental expenses across the business of approximately   million while aralez has made significant reductions to its expenses the company plans to invest an additional  million to support a successful phased launch of zontivity that commenced on april   which the company views as an increasingly attractive opportunity the company also continues to assess various business development opportunities with the goal of providing improved cash flow and an enhanced platform for creating value first quarter  financial results aralez’s financial results for the three months ended march   include the operations of tribute pharmaceuticals canada inc tribute from february   the closing date of the pozen and tribute merger transaction the merger through march   but do not include the results of zontivity or toprolxl and its currently marketed authorized generic the toprolxl franchise as these acquisitions were completed on september   and october   respectively aralez’s financial results for the three months ended march   include the results of tribute zontivity and the toprolxl franchise total revenues for the three months ended march   were   million compared to  million for the three months ended march   net product revenues of  million for the three months ended march   primarily related to the product portfolio acquired with the acquisition of tribute as well as net product revenues from yosprala and fibricor® other revenues of   million for the three months ended march   were comprised of net revenues of   million from the acquisitions of the toprolxl franchise and zontivity which are recorded net of related cost of product revenues and fees paid during the respective transition service periods and vimovo  royalties of  million pursuant to the company’s agreement with horizon in the us subject to certain conditions described in our public filings aralez is guaranteed a quarterly minimum royalty amount calculated based on a minimum annual royalty of  million which was reflected in the company’s first quarter results net product revenues of  million for the three months ended march   related to the tribute product portfolio acquired in the merger which was completed on february   other revenues of  million for the three months ended march   were comprised solely of vimovo royalties cost of product revenues were  million for the three months ended march   compared to  million for the three months ended march   the increase related primarily to costs of product revenues for the full quarter in  from the company’s product portfolio that was acquired as part of the merger in february  sga expenses were  million for the three months ended march   compared to  million for the three months ended march   the decrease in sga expenses was primarily driven by costs related to the merger in the prior year of approximately  million partially offset by increased costs related to the build out of our us sales force in  and increased promotional expenses in the us during the first quarter of  rd expenses for the three months ended march   were  million compared to  million for the three months ended march   the decrease related primarily to higher costs incurred in the first quarter of  for yosprala in advance of its us approval in september  amortization of intangible assets of  million for the three months ended march   related to the acquisitions of tribute zontivity and the toprolxl franchise amortization of intangible assets for the three months ended march   of  million related solely to the acquisition of tribute page    the change in fair value of contingent consideration of  million for the three months ended march   related to accretion for the toprolxl franchise and zontivity acquisitions there was no expense related to fair value changes in contingent consideration for the three months ended march   interest expense of  million for the three months ended march   was primarily attributable to the borrowing of  million under the company’s credit facility in the fourth quarter of  in connection with the acquisitions of zontivity and the toprolxl franchise and  million convertible notes interest expense of  million for the three months ended march   related to the  million convertible notes other income net for the three months ended march   was  million compared to  million for the three months ended march   a decrease of  million the decrease principally related to a  million decrease in the fair value of the warrants liability acquired from tribute during the prior year offset by a  million gain from the sale of a building in london ontario during the three months ended march   the net loss for the three months ended march   was   million or  loss per share on a fully diluted basis compared to a net loss for the three months ended march   of  million or  loss per share on a fully diluted basis adjusted ebitda was  million for the three months ended march   compared to adjusted ebitda of  million for the three months ended march   balance sheet as of march   approximately  million of the company’s common shares were issued and outstanding and the company had cash and cash equivalents of approximately  million updated  guidance aralez’s estimates are based on projected results of the company for the year ending december   and reflect management’s current beliefs and expectations about among other things prescription trends competition pricing levels inventory levels and anticipated future events the company’s guidance on adjusted ebitda includes among other things costs to support the commercialization efforts with respect to yosprala zontivity and the canadian product portfolio as well as costs to support the global corporate structure it excludes sharebased compensation expense and certain discrete costs including merger and product acquisitionrelated expenses see “use of nongaap financial measures” below for the year ending december   assuming among other factors more particularly set out in “cautionary note regarding forwardlooking statements” below the company currently expects ·  net revenues to be in a range of  million to  million and · updated  adjusted ebitda to be in a range of  million to  million see the table below for a comparison of the company’s original  guidance compared to the updated  guidance           measure       original guidance       updated guidance net revenues    million to  million    million to  million adjusted ebitda    million to  million    million to  million   first quarter results webcast aralez will host a webcast this morning may   at  am et to present results for the first quarter  the webcast can be accessed live and will be available for replay at wwwaralezcom conference call details date tuesday may   time  am et dialin us ‑‑ dialin international ‑‑ page    about aralez pharmaceuticals inc aralez pharmaceuticals inc nasdaq arlz tsx arz is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients’ lives while creating shareholder value by acquiring developing and commercializing products primarily in cardiovascular pain and other specialty areas aralez’s global headquarters is in ontario canada the us headquarters is in princeton new jersey and the irish headquarters is in dublin ireland more information about aralez can be found at wwwaralezcom  use of nongaap financial measures the company has presented certain nongaap financial measures including adjusted ebitda as defined below these nongaap financial measures exclude certain amounts expenses or income from the corresponding financial measures determined in accordance with accounting principles generally accepted in the us gaap adjusted ebitda for the company is defined as net income loss before income taxes interest expense and financing costs depreciation and amortization stockbased compensation and gains or losses related to warrants changes to the fair value of contingent consideration restructuring costs retention costs impact of an acquisition of a business or product including transaction related expenses acquired inprocess rd and tax equalization payments interest income the impact of changes in foreign currency rates asset impairment charges losses or gains on sale of assets losses or gains on extinguishment or modification of debt and the impact of a sale or disposition of a business or product including discontinued operations management believes this nongaap information is useful for investors taken in conjunction with gaap financial statements because it provides greater transparency regarding the company’s operating performance by excluding i noncash expenses that are substantially dependent on changes in the market price of our common shares and ii discrete items such as merger and acquisitionrelated costs including transaction fees and severance and retention expenses that may not be consistently recurring management uses these measures among other factors to assess and analyze operational results and to make financial and operational decisions nongaap information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company’s operating results as reported under gaap not as a substitute for gaap in addition these nongaap financial measures are unlikely to be comparable with nongaap information provided by other companies the determination of the amounts that are excluded from nongaap financial measures is a matter of management judgment and depends upon among other factors the nature of the underlying expense or income amounts reconciliations between nongaap financial measures and the most comparable gaap financial measures are included in the tables accompanying this press release cautionary note regarding forwardlooking statements this press release includes certain statements that constitute “forwardlooking statements” within the meaning of applicable securities laws forwardlooking statements include but are not limited to statements regarding the company’s  expectation to reduce  operating expenses by approximately  million through its cost savings plan of which approximately  million was included in our original  adjusted ebitda guidance  including a decrease of approximately  million expected in  due to the previously announced sales force reduction  million on an annual basis a decrease of approximately  million in  commercial spend and decreased  departmental expenses across the business of approximately  million that the company plans to invest an additional  million to support the successful phased launch of zontivity which the company views as an increasingly attractive opportunity the company’s  commitment to reaching breakeven this year on an adjusted ebitda basis that the company has identified other initiatives to drive an increase in profitability including an increased focus on the canadian core growth brands implementing our cost savings plan to further improve our cost structure and balance sheet to maximize and preserve financial flexibility that the company is currently implementing a bold and significant change to its pricing strategy for yosprala aimed at allowing all patients to access the product for only  per month regardless of coverage or copay level set by their insurer that this program will be available for all patients through retail pharmacies or through select national mail order partners  that we continue to look opportunistically at business development opportunities with a strong focus on value creating and transformative ma with the goal of enhancing shareholder value providing improved cash flows and an enhanced platform for creating value that page    the full launch of zontivity is expected in early june  with  sales representatives targeting approximately  physicians that deerfield partners remains fully supportive of aralez and its management team the extension of the va contract payments or potential payments under the nonexclusive japanese patent license entered into by pozen  the outlook for the company’s future business and financial performance including the company’s  updated  guidance on adjusted ebitda and net revenues our strategies plans objectives goals prospects future performance or results of current and anticipated products and other statements that are not historical facts and such statements are typically identified by use of terms such as “may” “will” “would” “should” “could” “expect” “plan” “intend” “anticipate” “believe” “estimate” “predict” “likely” “potential” “continue” or the negative or similar words variations of these words or other comparable words or phrases although some forwardlooking statements are expressed differently you should be aware that the forwardlooking statements included herein represent management’s current judgment and expectations and are based on current estimates and assumptions made by management in light of its experience and perception of historical trends current conditions and expected future developments as well as other factors that it believes are appropriate and reasonable under the circumstances but there can be no assurance that such estimates and assumptions will prove to be correct and as a result the forwardlooking statements based on those estimates and assumptions could prove to be incorrect accordingly actual results level of activity performance or achievements or future events or developments could differ materially from those expressed or implied in the forwardlooking statements material factors risks or assumptions that were applied or taken into account in providing updated financial guidance for the year ending december   including with respect to the statements that aralez’s net revenues are expected to be in the range of  million to  million and adjusted ebitda is expected to be in the range of  million to  million include but are not limited to i successfully integrating zontivity and the toprolxl franchise  ii expected costs to support the commercialization efforts with respect to yosprala fibricor zontivity in process of being relaunched and the canadian product portfolio as well as expected costs to support the global corporate structure iii the exclusion of any impact from additional potential strategic business transactions such as mergers acquisitions divestures or financings that may be consummated iv an increase in prescription trends and revenues for both yosprala and zontivity in  relative to  v with respect to the toprolxl franchise  pricing with respect to the ag business at or near current levels and pricing with respect to va business as reflected in our modified va national contract  vi our ability to source and qualify suppliers for our drugs including for yosprala vii our ability to mitigate legal and regulatory risks and uncertainties including ongoing litigation related to vimovo and yosprala that may negatively impact our expectations regarding our products and product candidates viii future performance of our commercialization partners being in line with our expectations and the impact such performance is anticipated to have being consistent with our expectations with respect to our revenue projections ix currency rates remaining at or near current levels for the remainder of fiscal  x ongoing operational activities to manage expenses and improve profitability and xi prescription trends competition pricing levels inventory and the anticipated timing of future product launches and events remaining in line with management’s current beliefs readers are cautioned that actual future operating results and economic performance of the company including with respect to our net revenues and adjusted ebitda for the year ending december   are subject to a number of risks and uncertainties including among other things those described below and could differ materially from what is currently expected as set out in this press release in addition our operations and  updated financial guidance involve risks and uncertainties many of which are outside of our control and any one or any combination of these risks and uncertainties could also affect whether the forwardlooking statements ultimately prove to be correct and could cause our actual results level of activity performance or achievements or future events or developments to differ materially from those expressed or implied by the forward looking statements these risks and uncertainties include without limitation our inability to maintain a sales force of sufficient scale for the commercialization of our products in a timely and costeffective manner our failure to successfully commercialize our products and product candidates competition including increased generic competition costs and delays in the development andor approval of our product candidates including yosprala in the eu including as a result of the need to conduct additional studies or due to issues with thirdparty api or finished product manufacturers or the failure to obtain such approval of our product candidates for all expected indications including as a result of changes in regulatory standards or the page    regulatory environment during the development period of any of our product candidates with respect to certain products dependence on reimbursement from thirdparty payors and the possibility of a failure to obtain coverage or reduction in the extent of reimbursement the inability to maintain or enter into and the risks resulting from our dependence upon collaboration or contractual arrangements necessary for the development manufacture commercialization marketing sales and distribution of any products including our dependence on astrazeneca ab and horizon pharma usa inc for the sales and marketing of vimovo our dependence on patheon pharmaceuticals inc for the manufacture of yosprala our dependence on scheringplough ireland company for the supply of zontivity and our dependence on astrazeneca ab for the manufacture and supply of toprolxl and its currently marketed authorized generic ag our dependence on maintaining and renewing contracts with customers distributors and other counterparties certain of which may be under negotiation from time to time including our inability to renew existing contracts on favorable terms and the risks that we may not be able to maintain our existing terms with certain customers distributors and other counterparties our ability to protect our intellectual property and defend our patents regulatory obligations and oversight failure to successfully identify execute integrate maintain and realize expected benefits from new acquisitions such as the acquisitions of tribute zontivity and toprolxl and its ag failure to realize the expected benefits of our initiatives to reduce costs and improve profitability fluctuations in the value of certain foreign currencies including the canadian dollar in relation to the us dollar and other world currencies changes in laws and regulations including tax laws and unanticipated tax liabilities and regulations regarding the pricing of pharmaceutical products risks related to our financing and liquidity general adverse economic market and business conditions and those risks detailed from timetotime under the caption “risk factors” and elsewhere in the company’s securities and exchange commission sec filings and reports and canadian securities law filings including in our annual report on form ‑k for the year ended december   and our quarterly report on form ‑q for the quarterly period ended march   which will be available on edgar at wwwsecgov on sedar at wwwsedarcom and on the company’s website at wwwaralezcom and those described from time to time in our future reports filed with the sec and applicable securities regulatory authorities in canada you should not place undue importance on forwardlooking statements and should not rely upon this information as of any other date we undertake no obligation to publicly update or revise any forwardlooking statements whether as a result of new information future events or otherwise unless required by law aralez pharmaceuticals us inc contact nichol l ochsner executive director investor relations  corporate communications ‑‑ nochsneraralezcom       financial tables to follow page    aralez pharmaceuticals inc condensed consolidated statements of operations unaudited in thousands except per share data                       three months ended march                          revenues             product revenues net         other revenues           total revenues net           costs and expenses             cost of product revenues exclusive of amortization shown separately below           selling general and administrative           research and development           amortization of intangible assets           change in fair value of contingent consideration          — total costs and expenses           loss from operations           interest expense           other expense income net           loss before income taxes           income tax expense           net loss                       basic net loss per common share         diluted net loss per common share         shares used in computing basic net loss per common share           shares used in computing diluted net loss per common share           page    aralez pharmaceuticals inc condensed consolidated balance sheets unaudited in thousands                          march        december             assets             cash and cash equivalents         accounts receivable net           inventory           prepaid expenses and other current assets           property and equipment net           goodwill           other intangible assets net           other longterm assets           total assets                       liabilities and shareholders’ equity             accounts payable         accrued expenses           shortterm contingent consideration           other current liabilities           longterm debt           deferred tax liability           longterm contingent consideration           other longterm liabilities           total liabilities           total shareholders’ equity           total liabilities and shareholders’ equity         page    aralez pharmaceuticals inc reconciliation of gaap to nongaap financial measures unaudited in thousands                       three months ended march                          net loss         sharebased compensation           severance and retention           depreciation and amortization expense           interest expense           change in fair value of contingent consideration          — change in fair value of warrants liability           transaction related expenses           excise tax equalization payments     —      other           income tax expense           adjusted ebitda         page    aralez pharmaceuticals inc reconciliation of gaap to nongaap financial measures unaudited in thousands                       updated  guidance range        low end      high end     year ended december     year ended december             net loss         sharebased compensation           severance and retention           depreciation and amortization expense           interest expense           change in fair value of contingent consideration           transaction related expenses           income tax expense           adjusted ebitda           page  aralez pharmaceuticals inc private company information  bloomberg july    am et pharmaceuticals company overview of aralez pharmaceuticals inc snapshot people company overview aralez pharmaceuticals inc operates as a specialty pharmaceutical company in the united states and canada it engages in acquiring developing and commercializing products primarily in cardiovascular disease pain and other specialty areas it offers yosprala for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events toprolxl a cardioselective betablocker indicated for the treatment of hypertension fibricor a fenofibric acid for the treatment of severe hypertriglyceridemia zontivity for the reduction of thrombotic cardiovascular events in patients cambia a nonsteroidal antiinflammatory drug nsaid for the acute treatment of migraine  aralez pharmaceuticals inc operates as a specialty pharmaceutical company in the united states and canada it engages in acquiring developing and commercializing products primarily in cardiovascular disease pain and other specialty areas it offers yosprala for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events toprolxl a cardioselective betablocker indicated for the treatment of hypertension fibricor a fenofibric acid for the treatment of severe hypertriglyceridemia zontivity for the reduction of thrombotic cardiovascular events in patients cambia a nonsteroidal antiinflammatory drug nsaid for the acute treatment of migraine attacks fiorinal and fiorinal c for the relief of tension type headaches and soriatane for the treatment of severe psoriasis and other disorders of keratinization it also markets bezalip sr a panperoxisome proliferatoractivated receptor activator to treat hyperlipidemia as well as to increase insulin sensitivity and decrease blood glucose levels for the patients with metabolic syndrome proferrin an iron supplement and blexten an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticaria in addition it commercializes yosprala for the secondary prevention of cardiovascular disease in patients at risk for gastric ulcers further its outlicensed products include vimovo for the relief of the signs and symptoms of osteoarthritis rheumatoid arthritis and ankylosing spondylitis as well as to decrease the risk of developing gastric ulcers in patients at risk of developing nsaidassociated gastric ulcers and treximet a migraine medicine the company was incorporated in  and is headquartered in mississauga canada detailed description  west credit avenuesuite mississauga on ln ecanadafounded in  employees phone  fax  wwwaralezcom key executives for aralez pharmaceuticals inc mr adrian adams chief executive officer and director age  total annual compensation k mr andrew i koven president and chief business officer age  total annual compensation k mr scott j charles chief financial officer age  total annual compensation k dr james patrick tursi md chief medical officer age  total annual compensation k mr mark a glickman chief commercial officer age  total annual compensation k compensation as of fiscal year  aralez pharmaceuticals inc key developments aralez pharmaceuticals inc announces national commercial launch of zontivity vorapaxar in us jun   aralez pharmaceuticals inc announced the national commercial launch of zontivity vorapaxar in the us will commence this week zontivity is the antiplatelet therapy that inhibits parmediated platelet aggregation in response to thrombin zontivity is a oncedaily agent indicated for the reduction of thrombotic cv events in patients with a history of myocardial infarction mi or in patients with peripheral arterial disease pad and should be used in combination with daily aspirin andor clopidogrel according to their indications or standard of care zontivity is a proteaseactivated receptor par antagonist indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction mi or with peripheral arterial disease pad zontivity should not be used in patients with a history of stroke transient ischemic attack tia or intracranial hemorrhage ich or active pathological bleeding zontivity has been shown to reduce the rate of a combined endpoint of cardiovascular death mi stroke and urgent coronary revascularization ucr aralez pharmaceuticals inc announces resignation of jason m aryeh as board member jun   aralez pharmaceuticals inc announced it received a written letter of resignation from jason m aryeh stating that he resigned effective immediately from his position on the board of directors of the company mr aryeh did not resign as a result of any current dispute or disagreement with the company aralez pharmaceuticals inc presents at jefferies  global healthcare conference jun  am may   aralez pharmaceuticals inc presents at jefferies  global healthcare conference jun  am venue grand hyatt  e nd st new york new york united states speakers adrian adams chief executive officer and director similar private companies by industry company name region  bc ltd americas everpets ltd americas  canada inc americas aaa heidelberg inc americas ab biotech inc americas recent private companies transactions typedate target no transactions available in the past  months request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact aralez pharmaceuticals inc please visit wwwaralezcom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close aralez pharmaceuticals inc arlzo company profile  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states profile aralez pharmaceuticals inc arlzo related topics stocksstock screenerhealthcarepharmaceuticals overview news key developments people charts financials analysts research pulse arlzo on nasdaq usd  jul  change  chg   prev close  open  days high  days low  volume  avg vol  wk high  wk low  full description aralez pharmaceuticals inc is a canadabased specialty pharmaceutical company the company focuses on acquiring developing and commercializing products in cardiovascular pain and other areas the companys products include fibricor cambia fiorinal fiorinal c soriatane bezalip sr neovisc uracyst durela proferrin resultz and collatamp g its development products include yosprala and bilastine fibricor fenofibric acid is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia and as a complementary therapy along with diet to reduce elevated lowdensity lipoprotein cholesterol ldlc total cholesterol totalc triglycerides tg and apolipoprotein b apo b fibricor is also used to increase highdensity lipoprotein hdl cholesterol hdlc in patients with hypercholesterolemia or mixed dyslipidemia cambia diclofenac potassium for oral solution is a nonsteroidal antiinflammatory drug nsaid » full overview of arlzo company address aralez pharmaceuticals inc  west credit ave suite mississauga   on   ln e p f  company web links home page officers  directors name compensation arthur kirsch  andrew koven  adrian adams  scott charles  jennifer armstrong  » more officers  directors aralez pharmaceuticals inc news » more arlzo news related topics stocksstock screenerhealthcarepharmaceuticals aralez pharmaceuticals inc nasdaqarlz quotes  news  google financecookies help us deliver our services by using our services you agree to our use of cookieslearn moregot itmy accountsearchmapsyoutubeplaynewsgmaildrivecalendargoogletranslatephotosmoreshoppingwalletfinancedocsbooksbloggercontactshangoutskeepeven more from googlesign inhidden fieldssearch financeadobe flash player is required for interactive charts allowfinancearalez pharmaceuticals incnasdaqarlzadd to portfoliocompanysummarynewsrelated companieshistorical pricesmarketsnewsportfoliosstock screenergoogle domestic trendsrecent quotes  daysyou have no recent quoteschg   aralez pharmaceuticals inc  public nasdaqarlz   watch this stock      after hours    jul  pm edt   nasdaq realtime data  disclaimer currency in usd range     week    open  vol  avg  mkt cap m pe      divyield      eps  shares  beta  inst own      news relevance date all news for aralez pharmaceuticals inc » subscribe advertisement events add arlz to my calendars aug   q  aralez pharmaceuticals inc earnings release  am edt  aug   q  aralez pharmaceuticals inc earnings call  am edt  jun   aralez pharmaceuticals inc at jefferies healthcare conference may   q  aralez pharmaceuticals inc earnings release may   q  aralez pharmaceuticals inc earnings call  may   aralez pharmaceuticals inc annual shareholders meeting may   aralez pharmaceuticals inc extraordinary shareholders meeting more events from dailyfinance »     address  west credit ave suite mississauga on ln ecanada phone fax website links httparalezcom external links analyst estimates  marketwatch sec filings  edgar online major holders  msn money research reports  reuters settings  technicals  link to this view volume delayed by  minsprices are not from all markets sources include six advertisement related companies show most recent quarter most recent annual add or remove columns save changes cancel sector healthcare  industry pharmaceuticals  nec more from factset » description aralez pharmaceuticals inc is a canadabased specialty pharmaceutical company the company focuses on acquiring developing and commercializing products in cardiovascular pain and other areas the companys products include fibricor cambia fiorinal fiorinal c soriatane bezalip sr neovisc uracyst durela proferrin resultz and collatamp g its development products include yosprala and bilastine fibricor fenofibric acid is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia and as a complementary therapy along with diet to reduce elevated lowdensity lipoprotein cholesterol ldlc total cholesterol totalc triglycerides tg and apolipoprotein b apo b fibricor is also used to increase highdensity lipoprotein hdl cholesterol hdlc in patients with hypercholesterolemia or mixed dyslipidemia cambia diclofenac potassium for oral solution is a nonsteroidal antiinflammatory drug nsaid more from reuters » officers and directors arthur s kirsch independent chairman of the board age  bio  compensation   reuters andrew i koven president chief business officer age  bio  compensation   reuters adrian adams chief executive officer director age  bio  compensation   reuters scott j charles chief financial officer senior vice president age  bio  compensation   reuters jennifer lou armstrong executive vice president  human resources and administration age  bio  compensation   reuters eric l trachtenberg chief compliance officer general counsel corporate secretary age  bio  compensation   reuters mark a glickman chief commercial officer age  bio  compensation   reuters james patrick tursi md chief medical officer age  bio  compensation   reuters kenneth b lee jr lead independent director bio  compensation   reuters neal franklin fowler independent director age  bio  compensation   reuters full list on reuters » google finance beta available in hong kong  canada  us  china  ukinformation is provided as is and solely for informational purposes not for trading purposes or advice and may be delayedto see all exchange delays please see disclaimer google  google home  blog  help  report a problem  privacy policy  terms of service